Objective: To describe the feasibility, success rate, and complications of Angio-Seal use following transfemoral transarterial chemoembolization (TACE) at University Medical Center Ho Chi Minh City.
Methods: This prospective single-arm observational study included 84 patients with hepatocellular carcinoma who underwent TACE via femoral arterial access with Angio-Seal closure from September 2025 to April 2026. The puncture site was assessed 3 hours after the procedure and hourly thereafter if complete hemostasis had not yet been achieved. All patients underwent 1-month follow-up with CT angiography of the vascular access site.
Results: The mean age was 62.7 ± 13.3 years, and 82.1% of patients were male. Technical success and post-deployment hemostatic success were both 100% (95% CI: 95.7–100%). The median time to complete hemostasis and ambulation was 4 hours (IQR: 3–6), with 59/84 patients achieving both outcomes within 4 hours. No access-site complications were observed (95% CI: 0–4.3%). Poisson regression with robust variance showed that each 1-unit increase in INR (RR=3.70; 95% CI: 2.28–6.01; p<0.001) and each 10-minute increase in procedure time (RR=1.29; 95% CI: 1.09–1.52; p=0.002) were independently associated with delayed complete hemostasis and ambulation.
Conclusion: Angio-Seal demonstrated high technical and hemostatic success in the study cohort. The findings regarding complications should be interpreted cautiously because of the small sample size and the absence of a comparison group.